1. Introduction {#sec1-microorganisms-07-00603}
===============

Brucellosis is considered as a common bacterial zoonotic disease of high prevalence in countries of the Middle East and the Mediterranean region, as well as some parts of Central and South America, Africa, and Asia \[[@B1-microorganisms-07-00603],[@B2-microorganisms-07-00603]\]. Brucellosis is caused by bacteria of various species of the genus *Brucella* (*B.*) that are genetically highly related \[[@B3-microorganisms-07-00603],[@B4-microorganisms-07-00603]\]. *Brucella* is a Gram negative, facultative intracellular pathogen classically causing infections in sheep and goats (*B. melitensis*), rams (*B. ovis*), bovines (*B. abortus*), canines (*B. canis*), pigs (*B. suis*), and rodents (*B. neotomae*) \[[@B5-microorganisms-07-00603],[@B6-microorganisms-07-00603]\]. Brucellosis also affects terrestrial wildlife (*B. microti*) and marine mammals (*B. ceti* and *B. pinnipedialis*) \[[@B7-microorganisms-07-00603]\]. However, the cross infection of animal species with brucellae has also been reported \[[@B8-microorganisms-07-00603]\]. Brucellosis in livestock is causing high economic losses to livestock industry due to poor health, debility and loss of quality livestock products \[[@B9-microorganisms-07-00603]\]. In humans, brucellosis causes severe acute febrile illness that becomes chronic if left untreated \[[@B10-microorganisms-07-00603]\].

In developing countries, brucellosis is common but neglected disease, which has been endemic in Egypt for thousands of years and is present with a high prevalence in animals today \[[@B11-microorganisms-07-00603],[@B12-microorganisms-07-00603],[@B13-microorganisms-07-00603],[@B14-microorganisms-07-00603]\]. Prevalence ranges from 2.47% to 26.66% in various livestock populations and this has a great socio-economic impact \[[@B15-microorganisms-07-00603]\]. In Egypt, *B. abortus*, *B. suis* and *B. melitensis* strains were isolated from livestock having high levels of phylogenetic variability within each species \[[@B12-microorganisms-07-00603]\]. The incidence of human brucellosis is 0.28--95 per 100,000 inhabitants per year in Egypt \[[@B16-microorganisms-07-00603],[@B17-microorganisms-07-00603]\]. Humans get infected via the ingestion of contaminated raw milk, unpasteurized dairy products, handling of infected animals, animal discharges or dealing with *Brucella* cultures \[[@B18-microorganisms-07-00603],[@B19-microorganisms-07-00603]\].

The diagnosis of brucellosis is still challenging and usually relies on serological tests \[[@B20-microorganisms-07-00603]\], which are applied in vitro (milk or blood). Exceptionally, in vivo (allergic tests) are used. The isolation of brucellae and detection of *Brucella* DNA by PCR are the methods that allow definitive diagnosis \[[@B21-microorganisms-07-00603]\].

Although confirmation of the disease is achieved by bacterial culture and identification, *Brucella* is difficult to grow and bacterial culturing is time consuming. Additionally, this method poses a risk to laboratory personnel and requires specific biosafety measures \[[@B22-microorganisms-07-00603]\]. Hence, culture and biochemical typing remain the "gold standard" for the diagnosis of *Brucella* infection \[[@B23-microorganisms-07-00603]\], including biochemical tests like CO~2~ requirement, H~2~S production, and dye sensitivity. Urease, oxidase, and catalase tests are also used for the typing of *Brucella* spp. \[[@B24-microorganisms-07-00603]\]. A comparatively new method like matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) has emerged for microbiological identification \[[@B25-microorganisms-07-00603]\]. It is an economical, easy, rapid and accurate method based on the automated analysis of the mass distribution of bacterial proteins \[[@B26-microorganisms-07-00603]\]. A recently published study indicates that MALDI-TOF MS can accurately identify 99.5% and 97% of *Brucella* strains at the genus and species level, respectively that minimizing laboratory hazards. However, there are limitations in terms of sub-species level identification \[[@B27-microorganisms-07-00603]\]. *Brucella* identification and species differentiation can be accomplished using genus-specific *Brucella* PCR (B4/B5), AMOS-PCR, and Bruce-ladder PCR \[[@B28-microorganisms-07-00603],[@B29-microorganisms-07-00603],[@B30-microorganisms-07-00603],[@B31-microorganisms-07-00603],[@B32-microorganisms-07-00603]\].

The intracellular location of brucellae in reticuloendothelial cells and their predilection sites (e.g., bone) limit the penetration of most antibiotics. Antimicrobial regimes with quinolones, doxycycline, rifampicin, streptomycin, and aminoglycoside alone or in combination are used to treat brucellosis \[[@B33-microorganisms-07-00603]\]. Regular treatment failure and numerous reports of relapses of brucellosis following therapy exist ranging from 5% to 15% in uncomplicated cases \[[@B34-microorganisms-07-00603]\]. Recently, the antimicrobial resistance in *Brucella* is emerging in brucellosis endemic regions of the world (e.g., Egypt, Qatar, Iran, Malaysia, and China) \[[@B34-microorganisms-07-00603]\].

There is no proper legislation in Egypt regulating the use of antimicrobials. Some compounds such as quinolones, tetracycline, beta-lactams, aminoglycosides and imipenem are still overused non-therapeutically in Egypt to treat various human infections \[[@B35-microorganisms-07-00603],[@B36-microorganisms-07-00603],[@B37-microorganisms-07-00603]\]. This improper use of antimicrobials results in the emergence of multidrug resistant bacteria \[[@B38-microorganisms-07-00603],[@B39-microorganisms-07-00603],[@B40-microorganisms-07-00603],[@B41-microorganisms-07-00603]\]. The use of antimicrobials in farm animals to promote growth or as prophylaxis also contributes to the development of resistant bacteria and plays a key role in their spread along the food chain \[[@B42-microorganisms-07-00603]\]. Antimicrobial resistance in zoonotic pathogens is an additional risk because it will limit disease treatment options in public health and veterinary settings \[[@B43-microorganisms-07-00603]\]. None of the available studies highlights detailed antimicrobial susceptibility patterns of *Brucella* isolates from livestock in Egypt.

The use of antimicrobial susceptibility testing is the solution for appropriate control and treatment of brucellosis \[[@B44-microorganisms-07-00603],[@B45-microorganisms-07-00603]\]. Micro-dilution and/or gradient strip (*E*-test) methods are used to establish minimum inhibitory concentration (MIC) for antimicrobials \[[@B45-microorganisms-07-00603],[@B46-microorganisms-07-00603]\]. PCR assays and the subsequent sequencing of genes associated with resistance are used to identify the genetic bases of resistance \[[@B47-microorganisms-07-00603],[@B48-microorganisms-07-00603],[@B49-microorganisms-07-00603]\].

Resistance to commonly used antimicrobials is mediated by mutations of *rpo*B gene (rifampicin), *gyr*A, *gyr*B, *par*C, *par*E genes (quinolones), *erm*, *mef*, *msr* (macrolides) or the presence of *tet* genes (tetracyclines), *mecA* (beta-lactams) and *flo*A (trimethoprim) \[[@B50-microorganisms-07-00603]\]. Mutations in the *rpo*B and *gyr*A genes may occur naturally or can be induced in vitro \[[@B45-microorganisms-07-00603],[@B47-microorganisms-07-00603],[@B51-microorganisms-07-00603],[@B52-microorganisms-07-00603]\].

This study aimed to isolate, identify and biotype *Brucella* strains from livestock in various regions of Egypt. Antimicrobial resistance and its genetic basis are to be investigated in the gained *Brucella* isolates.

2. Materials and Methods {#sec2-microorganisms-07-00603}
========================

2.1. Isolation and Identification {#sec2dot1-microorganisms-07-00603}
---------------------------------

A total of 34 suspected *Brucella* isolates were recovered from clinical specimens of lymph nodes, milk and fetal stomach contents from infected cattle, buffaloes, sheep and goats located in Giza, Beheria, Asyut, Qalyubia, Beni-Suef, Ismailia, Dakahlia, and Monufia governorates/districts in Egypt ([Table 1](#microorganisms-07-00603-t001){ref-type="table"}).

Bacterial isolation and identification were performed in Biological Safety Level-3 (BSL-3) laboratory. Isolates were inoculated on calf blood agar, *Brucella* medium and *Brucella* selective medium plates (Oxoid GmbH, Wesel, Germany) at 37 °C in the absence and presence of 5--10% CO2 for up to 2 weeks. Typically, round, glistening, pinpoint and honey drop-like cultures were picked and stained with Gram and modified Ziehl-Neelsen staining (MZN) methods. Subsequent biochemical tests, motility test, hemolysis on blood agar and agglutination with monospecific sera were performed \[[@B24-microorganisms-07-00603],[@B53-microorganisms-07-00603]\]. Isolates were stored at −20 °C for further processing.

### Identification by MALDI-TOF MS

Bacterial identification was additionally carried out using MALDI-TOF MS as described previously \[[@B27-microorganisms-07-00603],[@B54-microorganisms-07-00603]\]. Briefly, pure cultures of suspected *Brucella* were obtained by incubating inoculated chocolate PolyViteX (PVX) agar plates (bioMérieux, Marcy-l'Étoile, France) for 48 h at 37 °C in the presence of 5% CO~2~. Samples were reliably inactivated in Biological Safety Level-3 laboratory. Approximately 10 colonies from culture medium were suspended in 50 μL of sterile HPLC water and mixed carefully. Formic acid (*v*/*v* 70%) was added for the inactivation of brucellae and for extraction of proteins. Then, 1 μL of tested sample and *Brucella* reference strains were added onto spots of a steel target plate. After inactivation, the plate was dried at room temperature followed by the addition of 0.5 μL of 100% ethanol to each well. Finally, spots were overlaid with 1 μL of reconstituted alpha-cyano-4-hydroxycinnamic acid (Bruker Daltonics, Billerica, MA, USA).

Spectra were acquired with an Ultraflex instrument (Bruker Daltonics GmbH, Bremen, Germany). Analysis was done with the Biotyper 3.1 software (Bruker Daltonics GmbH, Germany) as per the manufacturer's instructions to exclude spectra with outlier peaks or anomalies.

Logarithmic score values (0--3.0) were determined by automatically calculating the proportion of matching peaks and peak intensities between the test spectrum and the reference spectra in the database. The identification was considered reliable when the score between 2.3 and 3.0. A logarithmic score of 1.7--2.299 was reported as 'probable genus identification', indicating that identification was reliable only at the genus level. When the logarithmic score was \<1.7, the spectrum was reported as 'not reliable identification', indicating that sample could not be identified.

2.2. Genomic DNA Extraction and Purification {#sec2dot2-microorganisms-07-00603}
--------------------------------------------

DNA was extracted from heat inactivated pure *Brucella* culture (biomass) using the HighPure PCR Template Preparation Kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. DNA quantity and purity were determined using a NanoDrop™ 1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, USA).

2.3. Molecular Identification and Differentiation {#sec2dot3-microorganisms-07-00603}
-------------------------------------------------

The presence of the *Brucella* genus-specific *bscp31* gene \[[@B55-microorganisms-07-00603]\] and *Brucella*-specific insertion sequence 711 (IS*711*) \[[@B29-microorganisms-07-00603]\] was investigated for *Brucella* genus identification. Briefly, PCR was performed using 25 µL reaction mixture containing 18.3 µL HPLC water, 2.5 µL 10x PCR buffer (Genaxxon bioscience GmbH, Ulm, Germany), 1 µl of 10mM dNTP (Thermo Fisher Scientific, USA), 1 µL each forward (5′-TGG CTC GGT TGC CAA TAT CAA-3′) and reverse primer (5′ CGC GCT TGC CTT TCA GGT CTG-3′) (Jena Bioscience, Germany), 0.2 µL of 5U/µL Taq-polymerase (Genaxxon bioscience GmbH, Ulm, Germany) and 1 µL DNA template.

PCR condition was initiated by initial denaturation at 93 °C for 5 min, followed by 35 cycles of denaturation at 90 °C for 60 s, annealing at 60 °C for 60 s and elongation at 72 °C for 60 s and final elongation step at 72 °C for 5 min. PCR products (223 bp) were analyzed on 1.5% agarose gel, stained with ethidium bromide, and visualized under UV light.

The AMOS-PCR was performed to differentiate *Brucella* species \[[@B29-microorganisms-07-00603],[@B32-microorganisms-07-00603]\] followed by a multiplex Bruce-ladder PCR assay for strain and biovar typing \[[@B30-microorganisms-07-00603],[@B56-microorganisms-07-00603]\]. The list of primers and primer sequences for AMOS-PCR and Bruce-ladder PCR were geared from previously published \[[@B29-microorganisms-07-00603]\] and \[[@B30-microorganisms-07-00603]\], respectively. Briefly, for AMOS-PCR, PCR was performed using 25 µL reaction mixture containing 9.5 µL HPLC water, 12.5 µL of 2x Qiagen Master mix (Qiagen, Germany), 1 µL of 10 pmol primer mix and 2 µL DNA template. Initial denaturation at 95 °C for 5 min, was followed by 30 cycles of denaturation at 95 °C for 60 s, annealing at 58 °C for 2 min and elongation at 72 °C for 2 min and a final elongation step at 72 °C for 5 min. The Bruce-ladder PCR was performed using 12.5 µL reaction mixture containing 4.25 µL HPLC water, 6.25 µl of 2x Qiagen Master mix (Qiagen, Germany), 1 µL of 2 pmol/µL primer mix and 1 µL DNA template. Initial denaturation at 95 °C for 15 min, was followed by 25 cycles of denaturation at 94 °C for 30 s, annealing at 58 °C for 90 s, elongation at 72 °C for 3 min and a final elongation step at 72 °C for 10 min.

The PCR products from each PCR were separated by electrophoresis using 1.5% agarose gels (120 V for 60 min for conventional and AMOS-PCR and 130 V for 60 min for Bruce-ladder PCR). Gels were stained with ethidium bromide and photographed using a gene snap camera (Syngene Pvt Ltd., Cambridge, UK).

2.4. Antimicrobial Susceptibility Testing {#sec2dot4-microorganisms-07-00603}
-----------------------------------------

The antimicrobial susceptibility of *B. melitensis* and *B. abortus* isolates was performed against eight clinically relevant antimicrobial agents (chloramphenicol, ciprofloxacin, erythromycin, gentamicin, imipenem, rifampicin, streptomycin and tetracycline) using gradient strip method (E-test, bioMerieux, Marcy L'Etoile, France) as described previously \[[@B48-microorganisms-07-00603]\]. Briefly, a suspension of bacteria adjusted to 0.5 McFarland standard units was inoculated on Mueller-Hinton plates (Oxoid GmbH, Wesel, Germany) supplemented with 5% sheep blood and the gradient strips were applied. The plates were incubated at 37 °C with 5% CO~2~ for 48 h before reading. As MIC breakpoints for clinically used antimicrobials are not yet established for brucellae, the guidelines for slow-growing bacteria (*Haemophilus influenzae*) were used as an alternative \[[@B57-microorganisms-07-00603]\]. Quality control assays were performed using *E. coli* (161008BR3642, DSM 1103, ATCC 25922). The susceptibility profiles of *Brucella* isolates are presented as resistant and susceptible using minimum inhibitory concentrations (MIC), MIC~50~ and MIC~90~. The interpretations were performed using CLSI (The Clinical and Laboratory Standards Institute) \[[@B57-microorganisms-07-00603]\] and EUCAST (The European Committee on Antimicrobial Susceptibility Testing) \[[@B58-microorganisms-07-00603]\] using the criteria for slow growing bacteria. For rifampin, the strains were also classified as intermediate ([Table 2](#microorganisms-07-00603-t002){ref-type="table"}).

2.5. Molecular Detection of Antimicrobial Resistance-Associated Genes {#sec2dot5-microorganisms-07-00603}
---------------------------------------------------------------------

The PCR assays were performed as described previously \[[@B47-microorganisms-07-00603],[@B49-microorganisms-07-00603],[@B52-microorganisms-07-00603],[@B59-microorganisms-07-00603]\] to detect the antimicrobial resistance-associated genes, i.e., *cat*B, *gyr*A and *gyr*B, *rpo*B, *Aac* genes and *tet* genes for chloramphenicol, ciprofloxacin, rifampicin, streptomycin, gentamicin and tetracycline, respectively ([Supplementary Table S1](#app1-microorganisms-07-00603){ref-type="app"}). The primers used for amplification of the *rpo*B gene were designed by using submitted sequences for the *rpo*B gene of *B. abortus* (accession number AY562181) \[[@B47-microorganisms-07-00603]\]. PCR was performed using 25 µL reaction mixture containing 2x Qiagen Mastermix, 10 pmol each forward and reverse primer ([Table 1](#microorganisms-07-00603-t001){ref-type="table"}) and 5 µl DNA template. PCR was carried out by initial denaturation at 95 °C for 10 min, followed by 35 cycles of denaturation at 95 °C for 45 s, annealing (temperatures for each primer are given in [Table 1](#microorganisms-07-00603-t001){ref-type="table"}) for 60 s, elongation at 72 °C for 60 s and a final elongation step at 72 °C for 10 min. Twenty microliters of each reaction mixture were analyzed by gel electrophoresis (1% agarose gel with ethidium bromide).

2.6. PCR Amplicon Sequencing and Data Analysis {#sec2dot6-microorganisms-07-00603}
----------------------------------------------

Amplified PCR products for *gyr*A, *gyr*B and *rpo*B genes were purified using Qiagen QIAquick Gel extraction kit (Qiagen, Germany) and sent for sequencing (Eurofins Genomics Germany GmbH, Ebersberg, Germany). All consensus sequences were aligned and compared to the reference *Brucella* genes obtained from NCBI for detection and evaluation of nucleotide diversity and mutations using the software Geneious^®^ R11.1.5 (<https://www.geneious.com>). The sequences of *gyr*A (CP034103 and AE017223), *gyr*B (CP007760 and SDWB01000001) and *rpo*B (AY562181 and AY540346) genes of *B. melitensis* and *B. abortus* were geared from Gene bank and used as reference. Amino acid sequences were determined along with nucleotide sequences to identify missense mutations using BLAST.

3. Results {#sec3-microorganisms-07-00603}
==========

3.1. Microbiological Identification {#sec3dot1-microorganisms-07-00603}
-----------------------------------

Based on microbiological and biochemical characteristics, 21 strains were typed as *B. melitensis* biovar 3, eight strains were *B. abortus* biovar 1 and five samples were identified as *Achromobacter* species ([Table 1](#microorganisms-07-00603-t001){ref-type="table"}). The results of MALDI-TOF MS confirmed five isolates as *Achromobacter* species while the remaining 29 isolates were identified as *Brucella* species ([Table 1](#microorganisms-07-00603-t001){ref-type="table"}).

3.2. Molecular Identification and Differentiation {#sec3dot2-microorganisms-07-00603}
-------------------------------------------------

*Brucella* DNA of 24 isolates from cattle, three from buffaloes, one from a sheep and one from a goat were amplified with the genus specific assay. AMOS-PCR and Bruce-ladder PCR differentiated these 21 isolates as *B. melitensis* (17 from cattle, two from buffaloes, 1 from a sheep and 1 from a goat) and 8 isolates as *B. abortus* (seven from cattle and one from a buffalo). All isolates were confirmed as field strains ([Table 1](#microorganisms-07-00603-t001){ref-type="table"}).

3.3. Antimicrobial Susceptibility Profiling {#sec3dot3-microorganisms-07-00603}
-------------------------------------------

The in vitro MIC values against eight antimicrobial agents of all 29 *Brucella* isolates were determined by the gradient strip method (*E*-test). The MIC values along with MIC~50~ and MIC~90~ are summarized in [Table 2](#microorganisms-07-00603-t002){ref-type="table"}.

In this study, 76.19%, 19.04%, 76.19%, 66.66%, and 4.76% of the *B. melitensis* isolates were resistant to ciprofloxacin, erythromycin, imipenem, rifampicin/rifampin and streptomycin, respectively. While, 25%, 87.5%, 25%, and 37.5% of *B. abortus* isolates were phenotypically resistant to ciprofloxacin, erythromycin, imipenem and rifampicin/rifampin, respectively. All 29 *Brucella* isolates were sensitive to chloramphenicol, gentamicin, and tetracycline. Four isolates of *B. melitensis* (19.04%) and one *B. abortus* isolate showed multidrug resistance against ciprofloxacin (fluoroquinolones), erythromycin (macrolides), imipenem (carbapenems) and rifampicin (ansamycins).

3.4. Detection of Antimicrobial Resistance-Associated Genes and Mutations {#sec3dot4-microorganisms-07-00603}
-------------------------------------------------------------------------

Genes associated with antimicrobial resistance (*cat*B, *Aac* and *tet* (*tet*A, *tet*B, *tet*M and *tet*O) conferring resistance to chloramphenicol, streptomycin/gentamicin and tetracycline, respectively) were not identified either in resistant or sensitive isolates. The *gyr*A, *gyr*B and *rpo*B genes were amplified in all isolates.

Mutations in *rpo*B gene associated with a rifampicin-resistant *B. melitensis* and *B. abortus* phenotypes were detected at different positions ([Table 3](#microorganisms-07-00603-t003){ref-type="table"}).

Mutations in *gyr*A gene associated with phenotypic-ciprofloxacin resistance were detected at positions 167 (ATG to A[G]{.ul}G/methionine to arginine), 197 (CCC to C[G]{.ul}C/proline to arginine), 202 (CGC to [A]{.ul}GC/arginine to serine), 235 (GGT to [C]{.ul}GT/glycine to arginine), 941 (GCC to G[A]{.ul}C/alanine to aspartic acid), 944 (GTG to G[A]{.ul}G/valine to glutamic acid), 944-945 (GTG to G[GA]{.ul}/valine to glycine), 946 (GCC to [T]{.ul}CC/alanine to serine) and 962 (AAC to A[C]{.ul}C/asparagine to threonine) in *B. melitensis* ([Table 4](#microorganisms-07-00603-t004){ref-type="table"}).

Three-point mutations were also detected in *gyr*B gene at position 1141 (AAG to [G]{.ul}AG/Lysine to Glutamine), 1144 (ATC to [C]{.ul}TC/Isoleucine to leucine) and 1421 (TCA to T[T]{.ul}A/Serine to Leucine) in phenotypically resistant *B. melitensis* isolates ([Table 4](#microorganisms-07-00603-t004){ref-type="table"}).

Repeated mutations were detected at positions 676, 677 (TAC to [CT]{.ul}C/tyrosine to leucine) and 1435 (AAG to [C]{.ul}AG/lysine to glutamine) in the *rpo*B gene of phenotypic resistant *B. melitensis* isolates while the same was recorded at position 2890 (CGT to [G]{.ul}GT/arginine to glycine) in the *rpo*B gene of *B. abortus* isolates. No mutation was detected in *gyr*A and *gyr*B gene of *B. abortus* strains.

4. Discussion {#sec4-microorganisms-07-00603}
=============

Brucellosis is a zoonotic disease of public health importance and is still endemic in many countries including Egypt \[[@B17-microorganisms-07-00603],[@B20-microorganisms-07-00603]\]. In this study, the phenotypic and molecular characterization of *Brucella* isolates from cattle, buffaloes, sheep and goats obtained from different geographical locations of Egypt was performed. Additionally, the molecular basis of antimicrobial resistance in *Brucella* isolates from Egypt is reported for the first time. These results contribute to a better understanding of geographic transmission and spread of brucellae in livestock in Egypt and pave a way for specific treatment and control of the disease in animals and as well as in humans.

For the accurate diagnosis of brucellosis, isolation of bacteria or molecular proof along with suggestive clinical signs is needed. Brucellae were isolated in this study from milk, lymph nodes and fetal stomach contents as recommended in previous reports \[[@B24-microorganisms-07-00603],[@B60-microorganisms-07-00603]\].

Twenty-one *B. melitensis* bv3 and 8 *B. abortus* bv1 were isolated from cattle, buffaloes, sheep and goats from Giza, Beheria, Asyut, Qalyubia, Beni-Suef, Ismailia, Dakahlia and Monufia governorates. Previous reports were described previously that *Brucella* was prevailing in the country \[[@B12-microorganisms-07-00603]\]. The isolation of *B. melitensis* from cattle and buffaloes in this study may be attributed to mixed farming of large and small ruminants as mentioned previously \[[@B13-microorganisms-07-00603]\].

Still brucellosis is a challenge to treat in humans, particularly after delayed diagnosis of the infection. The WHO (World Health Organization) recommended treatment include high oral doses of rifampicin, doxycycline or tetracycline and trimethoprim-sulfamethoxazole. Although streptomycin and tetracycline are considered as powerful therapeutic agents against brucellosis, their higher toxicity limits their use \[[@B52-microorganisms-07-00603],[@B61-microorganisms-07-00603]\]. Quinolones are promising alternatives to treat human brucellosis as they have good bioavailability and affinity for bone and soft tissues \[[@B51-microorganisms-07-00603]\].

Only one study from Brazil reported reduced antimicrobial sensitivity in brucellae isolated from cattle \[[@B62-microorganisms-07-00603]\]. However, the emergence of brucellae isolated from humans phenotypically resistant to ciprofloxacin, gentamycin, streptomycin, rifampicin and trimethoprim-sulfamethoxazole was reported in Egypt, Iran, Qatar, China, Norway and Malaysia \[[@B46-microorganisms-07-00603],[@B48-microorganisms-07-00603],[@B63-microorganisms-07-00603],[@B64-microorganisms-07-00603],[@B65-microorganisms-07-00603]\]. Phenotypically rifampicin resistant *B. melitensis* isolates were also reported from Norway in imported cases from the Middle East, Asia or Africa \[[@B45-microorganisms-07-00603]\]. Probable rifampicin resistance was noted in 19% of a large collection of *B. melitensis* isolates from humans in Egypt between 1999 to 2007 \[[@B65-microorganisms-07-00603]\]. However, none of those isolates were investigated further to confirm the basis of resistance or reduced susceptibility.

In this study, a notable phenotypic resistance against ciprofloxacin (76.19%) was detected in *B. melitensis* strains isolated from animals. In contrast, none of the mentioned studies reported ciprofloxacin resistance in clinical isolates of humans and animals before. However, antimicrobial resistance against quinolones has been reported in in vitro studies of *B. melitensis* from Greece and France \[[@B49-microorganisms-07-00603],[@B52-microorganisms-07-00603]\].

An alarming high number of rifampicin resistant (66.66%) *B. melitensis* isolates was found in this study. Previous reports from Egypt (19%), \[[@B65-microorganisms-07-00603]\], Norway (24%) \[[@B45-microorganisms-07-00603]\] and Kazakhstan (26.4%) \[[@B66-microorganisms-07-00603]\] described comparatively low resistance. Hence, these findings are in agreement with previously published reports from Egypt that clearly showed an increase in antimicrobial resistance in various other human pathogens \[[@B37-microorganisms-07-00603]\]. Reduced rifampicin susceptibilities in *B. melitensis* strains were also reported from Iran, Malaysia, China, and Kazakhstan \[[@B46-microorganisms-07-00603],[@B48-microorganisms-07-00603],[@B63-microorganisms-07-00603],[@B64-microorganisms-07-00603],[@B66-microorganisms-07-00603]\].

The most striking finding of the present study was the emergence of phenotypic antimicrobial resistance against erythromycin (19.04%), imipenem (76.19%) and streptomycin (4.76%) in *B. melitensis* isolates. However, the increased use of these antimicrobials in Egypt in veterinary and human practices may be the cause of the emerging of this resistance \[[@B37-microorganisms-07-00603]\].

The phenotypic antimicrobial resistance against ciprofloxacin (25%), erythromycin (87.5%), imipenem (25%) and rifampicin (37.5%) of *B. abortus* isolated in this study was not proved previously. Multidrug resistant strains of *B. abortus* isolated from cattle in this study were reported previously in Brazil \[[@B62-microorganisms-07-00603]\]. Four isolates of *B. melitensis* and one isolate of *B. abortus* showed multidrug resistance against ciprofloxacin, erythromycin, imipenem and rifampicin. These findings are in agreement with the results of Barbosa Pauletti et al. who find corresponding resistance among *B. abortus* isolates from cattle in brazil \[[@B62-microorganisms-07-00603]\]. All *B. melitensis* and *B. abortus* isolates in this study were sensitive to chloramphenicol, gentamicin and tetracycline. These findings are comparable to previously published reports in Egypt, China, Qatar and Kazakhstan \[[@B46-microorganisms-07-00603],[@B48-microorganisms-07-00603],[@B65-microorganisms-07-00603],[@B66-microorganisms-07-00603]\].

The target for rifampicin action in *Brucella* as well as in other bacteria is the beta-subunit of the DNA dependent RNA polymerase (RNAP) encoded by *rpo*B gene \[[@B47-microorganisms-07-00603],[@B51-microorganisms-07-00603]\]. In this study, mutations were identified in *rpo*B gene associated with phenotypic rifampicin resistant *Brucella* strains isolated from clinical specimens of animals in Egypt. Mutations were detected in all phenotypically resistant brucellae. Multiple and variable mutations were noted in each isolate along with few commonly shared mutations among many isolates. Frequent mutations at positions 676, 677-TAC to [CT]{.ul}C (tyrosine to leucine, 38%) and 1435-AAG to [C]{.ul}AG (lysine to glutamine, 23.8%) in the *rpo*B gene of phenotypically resistant *B. melitensis* were detected. These mutations are different from previously reported mutations (in vitro mutations) associated with rifampicin resistance in *Brucella* \[[@B47-microorganisms-07-00603]\].

Johansen et al. reported mutations in phenotypic rifampicin resistant or intermediately resistant *B. melitensis* isolates \[[@B45-microorganisms-07-00603]\], which in agreement with the findings of this study with additional mutations were detected as well as in intermediate rifampicin resistant *B. melitensis*.

To the best of our knowledge, this study is the first report that proved mutations in the *rpo*B gene of rifampicin resistant *B. abortus* strains. Frequent mutations were detected at position 2890-CGT to GGT (arginine to glycine, 37.5%).

Fluoroquinolone/quinolone resistance in *Brucella* is multifactorial by nature in addition to obvious mutations of the *gyr*A, *gyr*B, *par*C and *par*E genes \[[@B51-microorganisms-07-00603],[@B52-microorganisms-07-00603]\]. In this study, the mutations in *gyr*A and *gyr*B genes in phenotypically resistant *B. melitensis* and *B. abortus* to ciprofloxacin were investigated. The mutations in *gyr*A did not correspond with fluoroquinolone resistance mutations described by Turkmani et al. \[[@B49-microorganisms-07-00603]\], although they investigated mutations in vitro selected fluoroquinolone resistant *Brucella* mutants. The mutations in the *gyr*B gene detected at positions 1141-AAG to GAG (lysine to glutamine), 1144-ATC to CTC (isoleucine to leucine) and 1421-TCA to TTA (serine to leucine) of *B. melitensis* considered as novel findings of this study. None of these mutations was detected in *B. abortus* strains in *gyr*A or *gyr*B genes. However, the role of *par*C, *par*E and efflux systems cannot be ruled out for fluoroquinolone resistance \[[@B51-microorganisms-07-00603]\] as we did not investigate the changes in *par*C and *par*E genes.

Genes responsible for resistance against chloramphenicol (*cat*B), gentamicin (*Aac*) and tetracycline (*tet*A, *tet*B, *tet*M and *tet*O) were not detected in all investigated *Brucella* isolated in this study, which in accordance with the phenotypic antimicrobial susceptibility results of isolated *Brucella* isolates. It is also worth mentioning that all resistant *Brucella* strains were isolated from animals and they showed resistance to antimicrobials clinically used in humans practice, suggesting that the source of these *Brucella* strains may be of human origin. These findings point to the fact that inter-species and intra-host species *Brucella* transmission is common, but spillback may occur also when chronic human brucellosis is mistreated and resistant strains are shedded \[[@B67-microorganisms-07-00603]\]. A likely scenario would be the animal keeper interface.

The emergence of antimicrobial resistance (AMR) in bacteria is a public health issue globally and already compromises the treatment options regarding effectiveness of antimicrobials and control of several bacterial infections especially caused by gram-negative bacteria \[[@B68-microorganisms-07-00603]\]. Wide spreading AMR in these bacteria is likely to persist and even worsen in future due to the uncontrolled use of antimicrobials. Rifampicin and ciprofloxacin are effective against intracellular bacteria like *Brucella* \[[@B33-microorganisms-07-00603]\]. Higher phenotypic resistance in *Brucella* against these antimicrobials is likely to limits the treatment effectiveness, owing to the increased number of infections. Emergence of multidrug resistance *Brucella* in livestock species in this study may pose serious threat to humans as these bacteria often transferred from animals to humans through food chain \[[@B69-microorganisms-07-00603]\]. Being a zoonotic pathogen and given the emergence of increased antimicrobial resistance in *Brucella* species, the situation with respect to hospital care may worsen and limits the treatment options in public health settings.

5. Conclusions {#sec5-microorganisms-07-00603}
==============

Brucellosis is a contagious and often communicable worldwide zoonosis with high morbidity and low mortality. There has been a tremendous increase in inter host-species infection in the recent decades, especially in developing countries when farm animal species are kept on the same premises without biosecurity precautions. The disease is endemic in Egypt and *B. melitensis* and *B. abortus* have been reported as the main causative agents of brucellosis in humans and animals. High phenotypic resistance against ciprofloxacin, erythromycin, and imipenem were detected in *Brucella* spp. isolated from different districts and animals species reflecting a broad geographical distribution. The molecular identification of mutations in antimicrobial resistance associated genes highlight the mechanism of resistance in *Brucella* spp. There is a need for further insights into the epidemiology and spread of antimicrobial resistant *Brucella* in Egypt. The WHO regimes have to be reevaluated and awareness among physicians about AMR needs to be raised.
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Microbiological and molecular identification of *Brucella* spp. isolated from animal species in Egypt.

  Sample ID   Animal Species   Origin of Sample   Type of Sample          Growth with CO~2~   Slide Agglutination A-M-R-Serum   MALDI-TOF MS   Molecular Identification                                                                          
  ----------- ---------------- ------------------ ----------------------- ------------------- --------------------------------- -------------- -------------------------- ----- -------- ------------------- ----------------------------------- -----------------
  18RB17227   Cattle           Giza               Lymph node              \+                  \+                                \+             ^a^+ve                     +ve   ^b^−ve   *B. melitensis 3*   *Brucella* spp. (*B. abortus*)      *B. melitensis*
  18RB17228   Cattle           Giza               Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp. (*B. abortus*)      *B. melitensis*
  18RB17229   Cattle           Giza               Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella melitensis*               *B. melitensis*
  18RB17230   Cattle           Giza               Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp. (*B. melitensis*)   *B. melitensis*
  18RB17231   Cattle           Giza               Lymph node              \+                  \+                                \+             −ve                        −ve   −ve      \* NA               *Achromobacter* spp.                -ve
  18RB17232   Cattle           Giza               Lymph node              \+                  \+                                \+             −ve                        −ve   −ve      NA                  *Achromobacter* spp.                -ve
  18RB17233   Cattle           Giza               Lymph node              +/−                 +/−                               +/−            +ve                        −ve   −ve      *B. abortus 1*      *B. abortus*                        *B. abortus*
  18RB17234   Cattle           Giza               Lymph node              \+                  \+                                \+             −ve                        −ve   −ve      NA                  *Achromobacter* spp.                -ve
  18RB17235   Cattle           Giza               Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp. (*B. microti*)      *B. melitensis*
  18RB17236   Cattle           Giza               Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp. (*B. melitensis*)   *B. melitensis*
  18RB17237   Cattle           Giza               Lymph node              \+                  \+                                \+             −ve                        −ve   −ve      NA                  *Achromobacter* spp.                -ve
  18RB17238   Cattle           Giza               Lymph node              \+                  \+                                \+             +ve                        −ve   −ve      *B. abortus 1*      *Brucella* spp. (*B. microti*)      *B. melitensis*
  18RB17239   Cattle           Giza               Lymph node              \+                  \+                                \+             −ve                        −ve   −ve      NA                  *Achromobacter* spp.                -ve
  18RB17240   Cattle           Beheira            Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp. (*B. microti*)      *B. melitensis*
  18RB17241   Cattle           Beheira            Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp. (*B. microti*)      *B. melitensis*
  18RB17242   Cattle           Beheira            Lymph node              +/−                 +/−                               +/−            +ve                        −ve   −ve      *B. abortus 1*      *B. abortus*                        *B. abortus*
  18RB17243   Cattle           Beheira            Lymph node              +/−                 +/−                               +/−            +ve                        −ve   −ve      *B. abortus 1*      *B. abortus*                        *B. abortus*
  18RB17244   Buffalo          Asyut              Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp. (*B. abortus*)      *B. melitensis*
  18RB17245   Buffalo          Asyut              Lymph node              +/−                 +/−                               +/−            +ve                        −ve   −ve      *B. abortus 1*      *B. abortus*                        *B. abortus*
  18RB17246   Goat             Beni-Suef          Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp. (*B. microti*)      *B. melitensis*
  18RB17247   Cattle           Asyut              Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp. (*B. melitensis*)   *B. melitensis*
  18RB17248   Cattle           Qalyubia           Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp. (*B. microti*)      *B. melitensis*
  18RB17249   Cattle           Qalyubia           Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp. (*B. melitensis*)   *B. melitensis*
  18RB17250   Sheep            Beni-Suef          Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp. (*B. melitensis*)   *B. melitensis*
  18RB17251   Cattle           Beni-Suef          Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp. (*B. microti*)      *B. melitensis*
  18RB17252   Cattle           Ismailia           Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp. (*B. melitensis*)   *B. melitensis*
  18RB17253   Cattle           Ismailia           Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp. (*B. abortus*)      *B. melitensis*
  18RB17254   Cattle           Ismailia           Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp.                     *B. melitensis*
  18RB17255   Cattle           Beheira            Fetal stomach content   +/−                 +/−                               +/−            +ve                        −ve   −ve      *B. abortus 1*      *B. abortus*                        *B. abortus*
  18RB17256   Cattle           Dakahlia           Lymph node              +/−                 +/−                               +/−            +ve                        −ve   −ve      *B. abortus 1*      *B. abortus*                        *B. abortus*
  18RB17257   Cattle           Monufia            Lymph node              +/−                 +/−                               +/−            +ve                        −ve   −ve      *B. abortus 1*      *B. abortus*                        *B. abortus*
  18RB17258   Cattle           Monufia            Milk                    \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp. (*B. abortus*)      *B. melitensis*
  18RB17259   Cattle           Qalyubia           Lymph node              +/−                 +/−                               +/−            +ve                        −ve   −ve      *B. abortus 1*      *B. abortus*                        *B. abortus*
  18RB17260   Buffalo          Qalyubia           Lymph node              \+                  \+                                \+             +ve                        +ve   −ve      *B. melitensis 3*   *Brucella* spp. (*B. microti*)      *B. melitensis*

\* NA-not applicable, ^a^ Positive, ^b^ Negative, ^c^ *Brucella* medium, ^d^ *Brucella* selective medium, ^e^ *Brucella* blood agar.
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###### 

Antimicrobial resistance profiles of 21 *B. melitensis* and 8 *B. abortus* isolated from livestock species in Egypt against 8 clinically used antibiotics using *E*-test. Breakpoint and Minimal Inhibitory Concentration (MIC~50~, MIC~90~) for *B. melitensis* and *B. abortus* used in this study according to CLSI and EUCAST recorded for *H. influenzae* \[[@B57-microorganisms-07-00603],[@B58-microorganisms-07-00603]\] were provided.

  Antibiotic        Class              Breakpoints   *B. melitensis*   *B. abortus*                                       
  ----------------- ------------------ ------------- ----------------- -------------- ------- ------ ------ ------ ------ ------
  Chloramphenicol   Phenicols          ≤2            4                 ≥8             0.0     1      2      0.0    0.25   0.5
  Ciprofloxacin     Fluoroquinolones   ≤0.06         −                 \>0.06         76.19   0.12   0.25   25.0   0.06   0.06
  Erythromycin      Macrolides         −             −                 ≥16            19.04   4      8      87.5   32     32
  Gentamicin        Aminoglycosides    −             −                 ≤4             0.0     11     11     0.0    0.12   0.5
  Imipenem          Carbapenems        ≤2            −                 \>2            76.19   8      8      25.0   1      4
  Rifampicin        Ansamycins         ≤1            2                 ≥4             66.66   4      8      37.5   2      4
  Streptomycin      Aminoglycosides    −             −                 ≤16            4.76    1      2      0.0    0.25   0.5
  Tetracycline      Tetracyclines      ≤2            4                 ≥8             0.0     0.06   0.12   0.0    0.03   0.12

−. Not determined
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Detection of mutations in *rpo*B gene associated with rifampicin resistance in *B. melitensis* and *B. abortus*.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ID          *Brucella* spp.   RIF Resistance   Mutation Sites   Mutation      Amino Acid Change                 NCBI (Accession No.)
  ----------- ----------------- ---------------- ---------------- ------------- --------------------------------- --------------------------------------------------
  18RB17227   *B. melitensis*   4                676, 677\        TAC to CTC\   Tyrosine to leucine\              MN544028, MN544042, MN544056, MN544070, MN544084
                                                 1816\            GAT to GAA\   Aspartic acid to glutamic acid\   
                                                 1818\            GTC to GCC\   Valine to alanine\                
                                                 1820, 1822\      GTT to ATA\   Valine to isoleucine\             
                                                 1824, 1825\      TAC to TTT\   Tyrosine to phenylalanine\        
                                                 1826, 1828\      CTG to GTT\   Leucine to valine\                
                                                 1829, 1831\      TCG to GAC\   Serine to aspartic acid\          
                                                 1835, 1837\      ATG to GGC\   Methionine to glycine\            
                                                 1838\            GAA to AAA\   Glutamic acid to lysine\          
                                                 1842, 1843       GAA to GGT    Glutamic acid to glycine          

  18RB17228   *B. melitensis*   4                676, 677\        TAC to CTC\   Tyrosine to leucine\              MN544029, MN544043, MN544057, MN544071, MN544085
                                                 3901, 3902       TAC to ACC    Tyrosine to threonine             

  18RB17229   *B. melitensis*   4                676, 677\        TAC to CTC\   Tyrosine to leucine\              MN544030, MN544044, MN544058, MN544072, MN544086
                                                 1011\            AAC to AGC\   Asparagine to serine\             
                                                 1456, 1458\      GAA to AAG\   Glutamic acid to lysine\          
                                                 1787\            AAG to ACG\   Lysine to threonine\              
                                                 2491             ACC to CCC    Threonine to proline              

  18RB17230   *B. melitensis*   8                676, 677\        TAC to CTC\   Tyrosine to leucine\              MN544031, MN544045, MN544059, MN544073, MN544087
                                                 1435\            AAG to CAG\   Lysine to glutamine\              
                                                 1798, 1799\      GGC to AAC\   Glycine to asparagine\            
                                                 1801, 1802\      AAG to GGG\   Lysine to glycine\                
                                                 1804, 1806\      GTG to CTT\   Valine to leucine\                
                                                 1807\            ACG to TCG\   Threonine to serine\              
                                                 2209, 2210       ATC to TCC    Isoleucine to serine              

  18RB17235   *B. melitensis*   \>8              676, 677\        TAC to CTC\   Tyrosine to leucine\              MN544032, MN544046, MN544060, MN544074, MN544087
                                                 1469             GTC to GGC    Valine to glycine                 

  18RB17236   *B. melitensis*   8                676, 677         TAC to CTC    Tyrosine to leucine               MN544033, MN544047, MN544061, MN544075, MN544089

  18RB17238   *B. melitensis*   16               677\             TAC to TTC\   Tyrosine to phenylalanine\        MN544034, MN544048, MN544062, MN544076, MN544090
                                                 1780\            TAT to GAT\   Tyrosine to aspartic acid\        
                                                 1786, 1788\      AAG to CAA\   Lysine to glutamine\              
                                                 2869, 2871       CGT to GGG    Arginine to glycine               

  18RB17240   *B. melitensis*   16               2494, 2496       TCG to CTC    Serine to leucine                 MN544035, MN544049, MN544063, MN544077, MN544091

  18RB17241   *B. melitensis*   6(8)             1435\            AAG to CAG\   Lysine to glutamine\              MN544036, MN544050, MN544064, MN544078, MN544092
                                                 2870, 2871       CGT to CCG    Arginine to proline               

  18RB17246   *B. melitensis*   4                676, 678\        TAC to CTT\   Tyrosine to leucine\              MN544037, MN544051, MN544065, MN544079, MN544093
                                                 1436, 1437\      AAG to ACA\   Lysine to threonine\              
                                                 2870\            CGT to CCT\   Arginine to proline\              
                                                 3898\            TAC to AAC\   Tyrosine to asparagine\           
                                                 3901             ACG to CCG    Threonine to proline              

  18RB17249   *B. melitensis*   4                1435, 1437\      AAG to GTA\   Lysine to valine\                 MN544038, MN544052, MN544066, MN544080, MN544094
                                                 2170\            GGC to CGC\   Glycine to arginine\              
                                                 2203, 2205\      ATC to TTT\   Isoleucine to phenylalanine\      
                                                 2869\            CGT to GGT\   Arginine to glycine\              
                                                 3152, 3153\      GTG to GGT\   Valine to glycine\                
                                                 3154, 3156\      CAG to GCA\   Glutamine to alanine\             
                                                 3157             CGC to AGC    Arginine to serine                

  18RB17253   *B. melitensis*   4                1435\            AAG to CAG\   Lysine to glutamine\              MN544039, MN544053, MN544067, MN544081, MN544095
                                                 1745             GCC to GGC    Alanine to glycine                

  18RB17258   *B. melitensis*   6                676, 677\        TAC to CTC\   Tyrosine to leucine\              MN544040, MN544054, MN544068, MN544082, MN544096
                                                 2501, 2502       CAC to CCA    Histidine to proline              

  18RB17260   *B. melitensis*   4                1435\            AAG to CAG\   Lysine to glutamine\              MN544041, MN544055, MN544069, MN544083, MN544097
                                                 3670, 3672       CAG to TAT    Glutamine to tyrosine             

  18RB17233   *B. abortus*      4                703, 704\        ACT to CTT\   Threonine to leucine\             MN544013,\
                                                 709, 710\        ACC to CAC\   Threonine to histidine\           MN544016,\
                                                 1457, 1458\      AAG to ACA\   Lysine to threonine\              MN544019,\
                                                 1460\            GAA to GGA\   Glutamic acid to glycine\         MN544022,\
                                                 2512\            ACC to CCC\   Threonine to proline\             MN544025
                                                 2515, 2517\      TCG to CTC\   Serine to leucine\                
                                                 2890, 2892\      CGT to GGG\   Arginine to glycine\              
                                                 3123\            GAC to GAG\   Aspartic acid to glutamic acid\   
                                                 3124, 3125       GAC to ATC    Aspartic acid to isoleucine       

  18RB17242   *B. abortus*      \>4              698, 699\        TAC to TTT\   Tyrosine to phenylalanine\        MN544014,\
                                                 1457, 1458\      AAG to ACA\   Tyrosine to threonine\            MN544017,\
                                                 1460\            GAA to GGA\   Glutamic acid to glycine\         MN544020,\
                                                 1789\            ATC to GTC\   Isoleucine to valine\             MN544023,\
                                                 1801\            TAT to GAT\   Tyrosine to aspartic acid\        MN544026
                                                 2887\            GAG to AAG\   Glutamic acid to lysine\          
                                                 2890             CGT to GGT    Arginine to glycine               

  18RB17245   *B. abortus*      4                709\             ACC to CCC\   Threonine to proline\             MN544015, MN544018, MN544021, MN544024, MN544027
                                                 2890             CGT to GGT    Arginine to glycine               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
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Detection of mutations in *gyr*A and *gyr*B genes associated with ciprofloxacin resistance in *B. melitensis.*

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  ID          *Brucella* spp.   CIPResistance   Gene        Mutation Sites   Mutation                    Amino Acid Change         NCBI (Accession No.)
  ----------- ----------------- --------------- ----------- ---------------- --------------------------- ------------------------- ----------------------
  18RB17230   *B. melitensis*   0.5             *gyr*A      167\             ATG to AGG\                 Methionine to arginine\   MN536677
                                                            197\             CCC to CGC\                 Proline to arginine\      
                                                            202\             CGC to AGC\                 Arginine to serine\       
                                                            235              GGT to CGT                  Glycine to arginine       

  18RB17235   *B. melitensis*   0.25            944, 945\   GTG to GGA\      Valine to glycine\          MN536678                  
                                                946         GCC to TCC       Alanine to serine                                     

  18RB17238   *B. melitensis*   0.25            941\        GCC to GAC\      Alanine to aspartic acid\   MN536679                  
                                                944         GTG to GAG       Valine to glutamic acid                               

  18RB17254   *B. melitensis*   0.12            962         AAC to ACC       Asparagine to threonine     MN536680                  

  18RB17230   *B. melitensis*   0.5             *gyr*B      1144             ATC to CTC                  Isoleucine to leucine     MN536681

  18RB17244   *B. melitensis*   0.25            1141        AAG to GAG       Lysine to Glutamine         MN536682                  

  18RB17252   *B. melitensis*   0.12            1421        TCA to TTA       Serine to Leucine           MN536683                  

  18RB17254   *B. melitensis*   0.12            1421        TCA to TTA       Serine to Leucine           MN536684                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------
